[Link].

com/scientificreports

OPEN Corticosteroid reduction by

addition of cetirizine and
montelukast in biopsy-proven
minimal-change nephrotic
syndrome concomitant with
allergic disorders
Yoichi Oshima   1,2*, Keiichi Sumida1,3, Masayuki Yamanouchi1, Noriko Hayami1,
Akinari Sekine   1, Hiroki Mizuno1, Masahiro Kawada1, Rikako Hiramatsu1, Eiko Hasegawa1,
Tatsuya Suwabe1, Junichi Hoshino   1, Naoki Sawa1, Takeshi Fujii4, Kenmei Takaichi1,5 &
Yoshifumi Ubara1,5
Recent reports suggest helper T-cell abnormalities in minimal-change nephrotic syndrome (MCNS),
which often complicate allergic disorders that show a similar helper T-cell profile with Th2/Th17
predominance. However, the effect of anti-allergy therapy on MCNS remains unknown. This
retrospective study included 51 patients with biopsy-proven MCNS recruited between November
2012 and October 2015, with follow-up through November 2017. We analyzed relapse and temporal
daily corticosteroid dose with and without co-administration of histamine H1 receptor antagonist,
cetirizine, and cysteinyl-leukotriene receptor antagonist, montelukast, as well as between baseline
and after follow-up. Thirteen patients were treated with cetirizine and montelukast in addition to
conventional therapy, whereas 38 patients were treated by conventional therapy only, consisting of
corticosteroids and immunosuppressants. To adjust for baseline clinical characteristics, a 1:1 propensity
score–matched model was applied. The clinical characteristics of the two groups after matching were
similar at baseline. The treatment group showed a significant reduction in the lowest daily dose of oral
prednisolone throughout the entire treatment course after the study compared to that of baseline
(p < 0.025), which was not observed in the control group (p = 0.37), and showed significantly higher
percentage of patients establishing corticosteroid-free state for the first time throughout the entire
treatment course by addition of cetirizine and montelukast compared to the control group (p < 0.025).
The study shows, for the first time, the steroid sparing effect of cetirizine and montelukast in addition
to conventional treatment in MCNS patients with concomitant allergies.

Minimal-change nephrotic syndrome (MCNS) or minimal-change disease is one of the major causes of nephrotic
syndromes. MCNS patients are generally responsive to corticosteroids and some may stay in remission after
tapering off corticosteroids; however, roughly more than half of the patients experience relapse during their clin-
ical course. These patients experience a variety of corticosteroid side effects.
The pathogenesis of MCNS remains obscure, but many clinical studies support T-cell abnormality in MCNS,
which was initially proposed by Shalhoub in 1974. Recent studies report type 1 and 2 helper T-cell (Th1 and

1
Nephrology Center, Toranomon Hospital, Tokyo, Japan. 2Department of Nephrology, Endocrinology, and
Metabolism, Keio University School of Medicine, Tokyo, Japan. 3Division of Nephrology, Department of Medicine,
University of Tennessee Health Science Center, Memphis, TN, USA. 4Department of Pathology, Toranomon Hospital,
Tokyo, Japan. 5Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan. *email: yoichi-
o-s@[Link]

Scientific Reports | (2020) 10:1490 | [Link] 1

[Link]/scientificreports/ [Link]/scientificreports

Th2, respectively) and type 17 helper T-cell and regulatory T-cell (Th17 and Treg, respectively) dysregulations
in human MCNS. Th2 cytokine upregulation and Th1 cytokine downregulation in human MCNS patients has
been suggested1–6, and Th17 cytokine upregulation and Treg downregulation has also been indicated7–9. Notably,
the transcription level of GATA-binding protein 3 (GATA-3), a master regulator of Th2 differentiation and tran-
scriptional activator of Th2 cytokines, such as interleukins (IL) 4, 5, and 1310,11, was significantly upregulated
in peripheral blood mononuclear cells (PBMCs) from MCNS patients in the nephrotic state compared with
remission state1. Meanwhile, retinoic acid receptor–related orphan receptor γt, a master regulator of Th17 cells,
was upregulated and a major transcription factor in Treg cells, forkhead box P3 (Foxp3), was downregulated in
PBMCs from MCNS patients7.
Likewise, Th1/Th2 and Th17/Treg imbalance with Th2 and Th17 predominance was reported in allergic dis-
eases such as asthma12,13, atopic dermatitis14, and allergic rhinitis15. In allergic diseases, many cytokines and mol-
ecules, including histamine and leukotriene, have been investigated rigorously. Histamine plays an important
role in building the Th2 state16 through both histamine H117 and H2 receptors18 and the Th17 state through
histamine H4 receptor19. Leukotriene also plays an important role in the allergic state shaping Th220 and Th1721
predominance.
However, the therapeutic effect of anti-allergy treatment for MCNS has not been explored before. There is
classical clinical knowledge that anti-histamines are frequently used for allergic rhinitis, anti-leukotrienes were
also much used for asthma, and both drugs were used for urticaria. Scientifically, recent systematic review and
meta-analysis have shown the following. Cetirizine is significantly effective for allergic rhinitis superior to mon-
telukast22,23 whereas montelukast provides distinct benefit for asthma24. Both cetirizine25 and montelukast26 was
effective for urticaria. For atopic dermatitis, which is thought to be strongly related to MCNS, beneficial evidence
was observed for cyclosporin A27, which is a common immunotherapy also for MCNS. Therefore, in this obser-
vational study, we retrospectively investigated if anti-allergy treatment by histamine H1 receptor antagonist, cet-
irizine, combined with cysteinyl-leukotriene receptor antagonist, montelukast, is effective in disease control for
adults with biopsy-proven MCNS.

Methods
Cohort definition.  Among 124 consecutive patients who presented with nephrotic syndrome and were diag-
nosed with new-onset or recurrent MCNS by renal biopsy from 1985 to 2015 at Toranomon Hospital, 65 patients
were lost to follow-up by November 2017 (i.e., the end of follow-up) due to sustained complete remission of
MCNS, cessation of hospital visit, or referral to other local clinics, and three patients died during the follow-up,
resulting in 56 patients who were followed up until November 2017 in our outpatient clinic. We considered
patients eligible for analysis if they met both of the following criteria between November 2012 and October 2015:
(1) de novo exposure to cetirizine and montelukast, defined as initiation of these drugs in patients who had not
been exposed to the drugs after the date of MCNS diagnosis and (2) disease remission and tapering of oral pred-
nisolone to ≤ 10 mg/day. Therefore, 51 patients were included in the final cohort (Fig. 1a). Patients were further
divided into two groups based on their exposure to cetirizine and montelukast: those treated with (treatment
group, n = 13) and without (control group, n = 38) cetirizine and montelukast (Fig. 1b). Observation period is
defined as the time of allocation/inclusion between November 2012 and October 2015 until November 2017 (i.e.,
the end of observation) (Fig. 1b). No de novo exposure was recorded between October 2015 and November 2017.
The Toranomon Hospital Ethical Committee reviewed and approved the protocol (approval code 1739-H/B),
and informed consent was obtained in the form of opt-out on the website. Those who rejected were excluded. All
methods were performed in accordance with the Declaration of Helsinki.

Definition of the outcomes.  The minimum prednisolone dose was defined as the lowest daily dose of
oral prednisolone throughout the treatment course, as shown in Fig. S1. Figure S1 shows tapering of prescribed
prednisolone dose per day (vertical axis) during the time course (horizontal axis) in an example of an MCNS
patient. First relapse as shown as an arrow with “Relapse 1” occurred when the prednisolone dose was 4 mg/day.
Second relapse, “Relapse 2,” and third relapse, “Relapse 3,” occurred when the dose was 7.5 mg/day and 6 mg/day,
respectively. Thus, the lowest daily dose of oral prednisolone throughout the treatment course is defined as 4 mg/
day in this patient. Fig. S2a illustrates an example of successful reduction of the minimum prednisolone dose after
the addition of cetirizine and montelukast treatment, and Fig. S2b shows an example of unsuccessful reduction of
minimum prednisolone dose. In Fig. S2a, the patient was given cetirizine and montelukast added to conventional
treatment in the yellow shaded period, resulting in successful tapering of prednisolone to corticosteroid free state,
which leads the lowest daily dose of oral prednisolone throughout the treatment course to zero from 4 mg/day.
In Fig. S2b, during the cetirizine and montelukast addition period shaded in yellow, fourth relapse, “Relapse 4,”
occurred when prescribed prednisolone dose was 5 mg/day, which did not lower the minimum dose of 4 mg/day
in the past. We scored this minimum dose both at baseline (before the yellow shaded period) and after the study
(the whole period) for all patients and considered the treatment effective if the minimum dose is tapered after the
study period. Co-primary outcomes were defined as (1) the lowest daily dose of oral prednisolone throughout the
entire treatment course after the study compared to that of baseline, and (2) percentage of patients establishing
corticosteroid-free state for the first time throughout the entire treatment course compared to the control group.
Other outcomes were defined as secondary outcomes as follows and used in sensitivity analysis. Relapse-free
rate was depicted in Kaplan-Meyer curve for the respective groups and compared by log-rank analysis.
Prednisolone dose on relapse was defined as prescribed prednisolone dose (mg/day) on relapse during the obser-
vation period (i.e. shaded period in yellow) in respective groups. Prednisolone tapering speed (mg/day/month)
was defined as reduced prednisolone dose from baseline divided by the observed period until the first relapse
during the follow-up or until November 2017.

Scientific Reports | (2020) 10:1490 | [Link] 2

[Link]/scientificreports/ [Link]/scientificreports

Figure 1. (a) Algorithm of this study. After excluding patients who were not eligible for analysis, 51 patients
were included in the study. Thirteen patients who had been prescribed with cetirizine and montelukast were
allocated to the treatment group, whereas the other 38 patients were allocated to the control group. After
observation until November 2017, 10 (77%) patients in the treatment group remained in remission, compared
with 27 (71%) patients in the control group. (b) Schematic diagram of this study for the two groups by timeline.
Patients were included in the study as soon as they fulfilled the inclusion criteria between November 2012 and
October 2015. Patients were followed up until November 2017.

We explored possible risk factors for relapse during the study period by single-factor Cox regression analysis
and logistic regression analysis using the data from the control group before matching. The factors analyzed
were age, estimated glomerular filtration rate (eGFR), urinary protein, number of past relapses per year, disease
duration, other immunosuppressants, concomitant allergic disorders, minimum prednisolone dose, prednisolone
dose at baseline, concomitant hypertension, dyslipidemia, diabetes mellitus, and hyperuricemia that required
medication, serum IgE level, eosinophil count, and possible factors that aggravate MCNS such as infection (mod-
erate or severe), irregular corticosteroid reduction, or new onset malignancy.
We also explored factors which have possible association with allergy complication for all patients at baseline
by multivariate logistic regression analysis.
Supplementary methods describe clinical and histological diagnosis, treatment course, data collection, and
statistical analyses.

Results
Propensity score matching.  There was an imbalance of clinical characteristics between the two groups at
baseline, as shown in Table S1. For comparison, we applied the 1:1 propensity score–matching method. We chose
the following 10 factors for matching based on potential risk by clinical experience that might influence relapses
and named this analysis as model 1: age, sex, eGFR, urinary protein, number of past relapses per year, follow-up

Scientific Reports | (2020) 10:1490 | [Link] 3

[Link]/scientificreports/ [Link]/scientificreports

Before matching After matching (model 1)

Treatment Control Stand Treatment Control Stand
(n = 13) (n = 38) diff (n = 13) (n = 13) diff
*Age at inclusion, years 48.2 ± 14.0 54.8 ± 17.3 −0.42 48.2 ± 14.0 51.3 ± 17.2 −0.20
*Sex prevalence, no. of men % 7, 54% 25, 68% −0.28 7, 54% 9, 69% 0.32
*eGFR at inclusion, ml/min/1.73 m2 86 ± 23 76 ± 17 0.49 86 ± 23 85 ± 11 0.09
*Urinary protein at inclusion, g/gCre 0.07 ± 0.12 0.12 ± 0.35 −0.19 0.07 ± 0.12 0.05 ± 0.07 0.20
Age at onset, years 31.1 ± 19.0 38.7 ± 19.0 −0.40 31.1 ± 19.0 35.0 ± 20.0 −0.20
Disease duration, months 205 ± 114 192 ± 156 0.09 205 ± 114 197 ± 112 0.09
Past relaplse, times 4.2 ± 3.3 2.7 ± 4.1 0.38 4.2 ± 3.3 4.3 ± 5.0 −0.04
*past relapse per year, times/yr 0.29 ± 0.19 0.15 ± 0.19 0.72 0.29 ± 0.19 0.27 ± 0.25 0.10
*Follow up period, months 44.6 ± 4.8 56.6 ± 10.2 −1.50 44.6 ± 4.8 54.7 ± 12.4 −1.07
*Other immunosupressants, no./% 6, 46% 10, 27% 0.41 6, 46% 7, 54% −0.15
*Comcomitant allergic disorders, no./% 13, 100% 20, 54% 1.30 13, 100% 13, 100% 0.00
Dyslipedemia, no./% 1, 8% 14, 38% −0.77 1, 8% 2, 15% −0.24
*minimum PSL dose, mg 0.83 ± 1.1 2.6 ± 2.9 −0.37 0.83 ± 1.1 1.08 ± 2.7 −0.12
*PSL dose at baseline, mg 4.1 ± 3.7 3.3 ± 3.7 0.21 4.1 ± 3.7 4.1 ± 3.8 0.00
IgE, U/mL 780 ± 643 496 ± 592 0.46 780 ± 643 865 ± 676 −0.13
Eosinophil,/microL 80 ± 62 224 ± 198 −0.98 80 ± 62 258 ± 200 −1.20
Infection, irregular PSL reduction, or malignancy, no./% 4, 31% 16, 42% −0.26 4, 31% 3, 23% 0.17

Table 1.  Clinical parameters before and after propensity score matching (model 1). Values are presented as
median ± standard deviation. Stand diff, standardized difference; eGFR, estimated glomerular filtration rate;
PSL, prednisolone; Cre, creatinine; *indicates items that were matched using the propensity-score analysis.
*matched items.

length, other immunosuppressants, concomitant allergic disorders, minimum prednisolone dose, and predniso-
lone dose at baseline. Table 1 shows the values of each factor before and after propensity score matching, validated
by standardized differences. It has been reported that a moderate standardized difference as large as 0.3 could
still be consistent with the propensity score model having been correctly specified when the matched sample
size is small28, as is applicable here. After matching with the above 10 factors, standardized differences improved
enough so that the two groups were fair to compare. Only follow-up length could not be matched enough due to
distinct differences between the two groups. The standardized difference for dyslipidemia, serum IgE level and
possible MCNS aggravating factors (infection, irregular corticosteroid reduction, or new onset malignancy) were
also improved after matching. More than 11 factors made the standardized difference too large, which did not
make the model fair. The outcome was analyzed between the two groups after matching, as will be described in
the following. Moreover, we selected two factors, serum IgE and possible MCNS aggravating factors (infection,
irregular corticosteroid reduction, or new onset malignancy) which could influence MCNS disease stability and
analyzed as propensity score matched model 2. The two groups were satisfactorily matched in terms of the two
factors, although other factors were not matched enough as shown in Table S2.

Results of the outcomes.  For the co-primary outcome (1), minimum prednisolone dose (i.e., the lowest
daily dose of oral prednisolone throughout the disease course) was significantly reduced after the study period
compared to that of the baseline in the treatment group (Fig. 2b, p = 0.0215), which was not observed in the con-
trol group (Fig. 2a, p = 0.37).
Table 2 shows the key clinical parameters of the propensity score–matched patients for the two groups
(model 1). In the treatment group, excluding three patients who experienced relapse, 10 (77%) of 13 patients
were maintained in corticosteroid-free remission for an average of 34 months at the end of the observation.
The three patients who relapsed were administered rituximab for treatment. On the other hand, for the con-
trol group (model 1), 6 (46%) of 13 patients remained in corticosteroid-free remission because five patients
experienced relapse and two patients were still on corticosteroids. Although there were almost twice as many
patients who reached the corticosteroid-free remission in the treatment group compared to the control group,
there was no statistically significant difference in overall percentage of patients between the two groups (77% vs
46%, p = 0.23). Notably, for the co-primary outcome (2), all seven who had never reached the corticosteroid-free
remission (i.e., those whose minimum prednisolone dose was not zero) in the treatment group had established
corticosteroid-free remission for the first time throughout the treatment course compared to one of four patients
in the control group, which was statistically significant (Fig. 2c, 100% vs 25%, p = 0.0242). Among the treatment
group, 1 (14%) of 7 patients who had never reached corticosteroid-free remission experienced relapse after pred-
nisolone had been tapered off, whereas the remaining 6 (86%) patients were still in corticosteroid-free remission
for an average of 34 months. Possible MCNS aggravating factors seen were herpes zoster virus reactivation, pye-
lonephritis, bronchiolitis, influenza, bladder cancer, rectum adenocarcinoma, and cervical cancer. Chronic side
effects of corticosteroids seen in these patients through the entire disease course were cataracts, glaucoma, osteo-
porosis, osteonecrosis of the femoral head, alopecia, muscle weakness, infection, hypertension and obesity. Thus,
both co-primary outcomes were statistically satisfied suggesting that cetirizine and montelukast combination has
a steroid sparing effect.

Scientific Reports | (2020) 10:1490 | [Link] 4

[Link]/scientificreports/ [Link]/scientificreports

Figure 2.  Results of the two groups after propensity score matching (model 1). (a,b) Lowest daily dose of oral
prednisolone throughout the entire disease history for the respective groups. (a) No improvement on lowest
prednisolone dose in disease history was observed in the control group (p = 0.37). (b) The improvement was
confirmed by addition of cetirizine and montelukast on top of standard corticosteroid therapy (p = 0.0215).
(c) The number of patients who reached PSL free state for the first time throughout their disease history. The
fraction of patients who reached PSL free was significantly higher in the treatment group compared to the
control group (p = 0.0242). (d) Survival curve of the two groups after propensity score matching. There was no
statistical significance between the two groups by log-rank test (p = 0.53). (e) The prednisolone dose on relapse
was significantly lower in the treatment group after propensity score matching (p = 0.035). (f) The prednisolone
tapering rate was significantly higher by addition of cetirizine and montelukast (p = 0.048). *, p < 0.05; NS, not
significant.

Secondary outcomes as described as follows were used as sensitivity analyses. Figure 2d shows that there
was no significant difference in relapse between the two groups after propensity score matching, as evaluated by
log-rank analysis (p = 0.53). As shown in Fig. 2e, however, the treatment group had significantly lower predni-
solone dose on relapse compared with that of the control group (p = 0.036), supporting that cetirizine and mon-
telukast possess a steroid sparing effect. This was also consistent with the result that the prednisolone tapering
speed was significantly higher in the treatment group compared to the control group (Fig. 2f, p = 0.048), because
fast tapering of corticosteroids triggers relapse in general clinical settings. As for histological features between
with and without allergies, there were no apparent difference that were detectable. All the kidney histology looks
the same with no apparent changes in glomeruli and interstitium. Interstitial fibrosis looks to be dependent on
underlying conditions such as benign nephrosclerosis and aging that are independent of MCNS. Only diffuse
podocyte foot process effacement is seen in electron microscopy. In fact, in the matched model 1, eGFR levels
which is closely associated with interstitial fibrosis are almost the same between the two groups as shown in
Table 1.
We analyzed the single-factor Cox regression analysis for relapse in the overall control group before matching
to detect the possible factors associated with relapse during conventional treatment only in our MCNS popu-
lation. The higher number of past relapses per year, immunosuppressant administration, and younger age at
baseline were significantly associated with relapse, as shown in Table 3, implying that these three factors may be
associated with high disease activity during the conventional treatment course. Logistic regression analysis of
relapse showed similar results as shown in Table S4. Immunosuppressants were given for frequently relapsing
patients in our hospital based on decisions of clinical experts. Because only 11 patients among the 38 patients in

Scientific Reports | (2020) 10:1490 | [Link] 5

[Link]/scientificreports/ [Link]/scientificreports

PSL dose Minimum PSL dose

After the
study, mg After
(PSL dose the Corticosteroid- Infection, irregular
Age at Complicated Immuno- Baseline, on relapse, Baseline, study, free remission, IgE, corticosteroid reduction,
Group Case baseline Sex allergy suppressants mg mg) mg mg months U/mL or malignancy
1 62 F AR MZR 1 0 1 0 42 620
2 41 M AD, As 1 relapse (0) 1 0 relapse (7) 12
Bladder cancer,
3 45 M AD, D CyA 10 relapse (0.5) 0 0 relapse 1438
bronchiolitis
4 30 M AR, F CyA 2 0 0 0 33 746
5 51 F AD, S 0.5 0 0 0 37 182
6 38 M AR 2 0 1 0 29 721
Treatment
7 44 M AD MZR, CyA 1 0 0.5 0 35
(model 1)
Herpes zoster virus,
8 39 F AD, AR, D, F Tac 10 relapse (0) 0 0 relapse (13) 33
influenza
9 54 M AR, S 10 0 0 0 25
10 32 F AD, AR, S 3 0 2 0 37 1366
11 82 F AD, D 8 0 4 0 37 93 Herpes zoster virus
12 43 M AD, AR 1.66 0 1.33 0 24 1937
13 65 F AR CyA 3 0 0 0 41 1430 Rectum adenocarcinoma
14 57 M D CyA 2 0 0 0 43
15 63 M AR, U 4 0 0 0 14
16 40 F D, F CyA 8 relapse (7) 3.5 3.5 relapse Cervical cancer
17 76 M As CyA 0 0 0 0 60 1190 pyelonephritis
18 64 F AR 0.5 0 0.33 0 41 770
19 47 F AD 0 0 0 0 60 1050
Control
20 41 M As CyA 1.5 relapse (1) 0.25 0.25 relapse 2186 Rectum adenocarcinoma
(model 1)
21 85 M S 1.5 1.5 0 0 on PSL 181
22 34 M As CyA 10 relapse (9) 0 0 relapse
23 19 M AR 10 relapse (5) 0 0 relapse 1650
24 42 M D CyA 10 relapse (9) 10 9 relapse 345
25 43 M U 3 2 0 0 on PSL 195
26 56 F AR, D CyA 2.5 0 0 0 54 220

Table 2.  Characteristics of propensity score matched patients (model 1). Clinical characteristics of propensity
score–matched patients (model 1). AD, atopic dermatitis; AR, allergic rhinitis; As, asthma; S, sinusitis; D, drug
allergy; F, food allergy; U, urticaria; PSL, prednisolone; CyA, cyclosporin A; MZR, mizoribine; Tac, tacrolimus.

the overall control group experienced relapse, we could not apply multivariable analysis due to a lack in the num-
ber of events. The result supports that the selection of the matching items were valid in our population because all
the three factors were included in the 10 items used for propensity score matching model 1. The treatment group
was excluded because anti-allergy agents may influence relapse in this case.
The results for matching model 2 are shown in Table S3 and Fig. S3. Minimum prednisolone dose was reduced
(Fig. S3b, p = 0.034) and more patients had achieved prednisolone free state for the first time (Fig. S3c, p = 0.046)
compared to the control group, which support the results of matching model 1. Although, the statistically signif-
icant level of p < 0.025 was not satisfied for these co-primary outcomes.
Table S5 shows the patient characteristics by separating if they have concomitant allergies or not at baseline.
Patients with concomitant allergies had characteristics as follows: significantly higher eGFR, younger age, higher
past relapse per year, higher percentage of cyclosporin A use, and less treatment-required dyslipidemia. We con-
ducted univariate logistic regression analysis for concomitant allergy and found that patients with allergy had
higher past relapse per year, more treatment-required hypertension, and tended to have less treatment-required
dyslipidemia, as shown in Table S6. Multivariate logistic regression analysis showed that the higher past relapse
per year and more frequent treatment-required hypertension was associated with allergy presence in MCNS
patients as shown in Table 4.

Discussion
We focused on the frequent complications of allergic diseases in MCNS and analyzed if anti-allergy treatment
could help control the disease activity of MCNS. We have selected patients by highly specific criteria composed
of clinical diagnosis of nephrotic syndrome and pathological diagnosis of MCNS, so that the effect of additional
therapy by cetirizine and montelukast could be assessed effectively. Through propensity score matching, we show,
for the first time, that the two agents significantly reduced the required corticosteroid dosage for maintaining
remission in repeated relapsing MCNS patients with concomitant allergic disorders, thus showing steroid sparing
effect.

Scientific Reports | (2020) 10:1490 | [Link] 6

[Link]/scientificreports/ [Link]/scientificreports

Variable Hazard ratio Lower 95% CI Upper 95% CI p value

Past relapse per year, 1 time per year 37.6 2.5 568.5 0.009
Immunosupressant, yes 4.0 1.2 13.2 0.022
Age, 10 years 0.67 0.47 0.97 0.032
Disease duration, 1 year 0.97 0.92 1.02 0.26
Urinary protein, 1 g/gCre 0.28 0.00 37.0 0.61
eGFR, 1 ml/min/1.73 m2 1.01 0.97 1.04 0.81
Minimum PSL dose, 1 mg 1.03 0.84 1.26 0.78
Concomitant allergic disorders, yes 1.08 0.33 3.57 0.89
PSL dose at baseline, 1 mg 1.11 0.95 1.29 0.18
Dyslipedemia, yes 0.54 0.14 2.03 0.36
Hyperurecemia, yes 0.75 0.10 5.87 0.78
Hypertension, yes 1.04 0.32 3.42 0.94
Diabetes mellitus, yes 1.77 0.54 5.81 0.35
Infection, irregular corticosteroid reduction, or malignancy, yes 1.40 0.30 6.46 0.67
IgE, 1 U/mL 1.00 1.00 1.00 0.40
Eos, 1/microg 1.00 1.00 1.00 0.52

Table 3.  Coefficient of Univariate analysis by cox regression analysis of relapse during observation for patients
without anti-allergy therapy. Coefficients of univariate Cox regression analysis of relapse during observation in
the control group. Past relapse per year, use of immunosuppressants, and age were statistically associated with
relapse. Cre, creatinine; eGFR, estimated glomerular filtration rate; PSL, prednisolone; CI, confidence interval.

Variable Odds ratio Lower 95% CI Upper 95% CI p value

Past relapse per year, 1 time per year 720 1.58 329000 0.035
Hypertension, yes 10.9 1.41 85 0.022
Dyslipedemia, yes 0.14 0.018 1.07 0.058

Table 4.  Coefficient of multivariate analysis by logistic regression analysis of concomitant allergy disorders
for all patients. Coefficient of multivariate logistic regression analysis of concomitant allergy disorders for all
patients. Past relapse per year and presence of treatment-required hypertension were statistically associated with
concomitant allergy in MCNS patients.

The effect of cetirizine or montelukast on corticosteroid dependency or relapse in MCNS patients have not
been described thus far. Zedan et al.29 conducted a randomized control study in childhood-onset nephrotic syn-
drome patients to determine if montelukast has beneficial effects on idiopathic nephrotic syndrome, but they did
not evaluate renal biopsies, corticosteroid dosage, and relapse profiles. Instead, they showed that plasma leukot-
riene B4 and LTC4/D4/E4 were significantly decreased by montelukast treatment29.
Here in the propensity score-matching model 1 as shown in Fig. 2, both the co-primary outcomes was sta-
tistically achieved: reduction in the lowest daily dose of oral prednisolone throughout the entire treatment
course after the study compared to that of baseline (p < 0.025), and higher percentage of patients establishing
corticosteroid-free state for the first time throughout the entire treatment course compared to the control group
(p < 0.025). The idea of steroid sparing effect of cetirizine and montelukast was also supported by significant dif-
ference in prednisolone dose on relapse (Fig. 2e) and corticosteroid tapering speed (Fig. 2f). As shown in Table 1,
the clinical characteristics of the two groups were satisfactorily similar at baseline. Other factors that were not
included in the ten factors used in model 1 such as IgE or possible MCNS aggravating factors (infection, irregular
corticosteroid reduction, or new onset malignancy) was also similar at baseline, although some of the IgE data
were missing. Eosinophil data were missing for 41 patients, so we could not apply for propensity score-matching
analysis. To focus on serum IgE level and possible MCNS aggravating factors that may influence MCNS relapse
as reported previously30–34, we created matching model 2 which results are shown in Table S2. Mostly different
patients were selected for model 2 in the control group, and only four patients were common in both model 1
and model 2 control groups. Patients with missing IgE were automatically excluded. If the two factors in model 2
had significant impact on relapse or corticosteroid sparing effect which overwhelms the therapeutic effect of cet-
irizine and montelukast, no therapeutic trend would be observed after the treatment. Contrary to this as shown
in Fig. S3, results of the model 2 were similar to that of model 1 which supported the results obtained in model
1. Although not statistically significant, trends were seen for the following. Minimum prednisolone dose was
reduced after the observation, percentage of patients whose prednisolone was off for the first time was higher,
prednisolone dose on relapse was lower, and prednisolone tapering rate was higher in the treatment group com-
pared to the control group, respectively. Altogether, in this propensity score-matching model as shown by model 1
and supported by model 2, cetirizine and montelukast have suggested for the first time the corticosteroid sparing
effect in allergy concomitant MCNS patients.

Scientific Reports | (2020) 10:1490 | [Link] 7

[Link]/scientificreports/ [Link]/scientificreports

In clinical settings, we occasionally encountered seasonal recurrence of MCNS occurring simultaneously with
seasonal rhinitis caused by pollens from cryptomeria or cypress; this finding is consistent with a previous report35.
Some of our patients reported fewer complaints, and some even experienced relief from symptoms, rhinitis and/
or itchiness from atopic dermatitis by the two medications. These symptomatic improvements may be associated
with better MCNS disease control for allergy-complicated MCNS patients. Regarding patient safety, no serious
or minor side effects were noted.
Additionally, we searched for possible factors associated with relapse and allergy, respectively. For relapse,
we applied univariate logistic regression or cox regression analysis for patients without anti-allergy therapy, and
the results are shown in Tables S4 and 3, respectively. Both analyses returned similar results. Possible association
was observed for past relapse per year, immunosuppressant use, and age all of which was included in the ten
factors for matching in model 1. We could not obtain a definite formula for relapse because multivariate analysis
could not be applied due to small number of relapses. For factors associated with allergy, results of univariate
and multivariate logistic regression analysis are shown in Tables S6 and 4, respectively. These results indicate that
frequent relapse may be associated with concomitant allergies, thus suggesting that anti-allergy therapy may have
possible benefit for controlling MCNS disease activity. Treatment-required hypertension was also associated with
allergies, although whether this association involves hypertension itself or anti-hypertensive drugs is unknown.
Regardless of the fact that IgE level is increased in patients with allergy disorders in general, it is interesting to see
that IgE level was not associated with allergy in this analysis. This suggested that MCNS itself may have increased
IgE level by its intrinsic pathophysiology. Possible molecular mechanisms of leukotriene, histamine, and MCNS
pathophysiology are discussed in the supplementary material.
This study had following limitations. First, the patient characteristics that were included indicate that the treat-
ment was effective for a confined population of multiple-relapse and allergy-concomitant MCNS patients with
prolonged disease duration. It is important that many patients who reached remission without relapse or who had
reached long remission were not included (Fig. 1a). The average disease duration was as long as 200 months in
the respective groups (Table 1). Second, the effect of older age may have influenced the reduced required corticos-
teroid dose because younger age had been identified as a possible risk factor in the single-factor Cox regression
model for the conventional treatment population (Table 3). However, the reduction of the lowest daily dose of oral
prednisolone throughout disease course, i.e. minimum prednisolone dose, was significantly reduced only in the
treatment group (Fig. 2a,b), suggesting that there was superiority in adding cetirizine and montelukast for disease
control compared to conventional treatment only. Third, the benefits gained by immunosuppressants were not
completely adjusted because we could only consider if patients took immunosuppressants or not. The difference
in effectiveness among the three types of immunosuppressants (cyclosporin A, mizoribine, or tacrolimus) for
MCNS has not been reported, as far as we know. Fourth, the follow-up period was shorter in the treatment group
compared to the control group. Although this may lead to increased relapse rate or lower prednisolone tapering
speed in the treatment group to some extent; this effect would be limited because the covered follow-up period
by the treatment group was as large as 82% of the period achieved by the control group. Moreover, a shorter
follow-up period would not influence the co-primary outcomes, i.e. minimum prednisolone dose after follow-up
or percentage of corticosteroid free condition establishment for the first time throughout the entire disease in
an unfavorable manner in the presented design. Fifth, regarding on regression analysis for relapse, we could not
apply multivariate analysis because there were not enough relapse cases. Lastly, this study was not a randomized
control trial, and its small sample size was also a shortcoming, therefore the accuracy of the conclusion may be
affected. On the other hand, the strengths of presented data could be stated as follows. First, the biopsy findings
and clinical diagnosis of nephrotic syndrome supports the definite diagnosis of MCNS and excludes apparent
FSGS. Second, data of long-term follow up is scares in general, therefore average follow up of 200 months at inclu-
sion and average follow up of 50 months for observation is valuable. These two features are expected to contribute
to the improved accuracy of the collected data. Also, we have conducted additional propensity score matching
(model 2) analysis to validate for other possible confounding factors associated with MCNS relapse which are
serum IgE and “possible MCNS aggravating factors (infection, irregular glucocorticoid reduction, and new onset
malignancy)”. Model 2 showed similar results (Fig. S3) providing a supportive data for model 1.
In conclusion, the addition of cetirizine and montelukast treatment for MCNS patients with prolonged disease
duration concomitant with allergic disorders was effective in reducing daily corticosteroid dosage. The effects
of the two agents on MCNS should be validated in other populations. Furthermore, whether these medications
are effective for early-phase MCNS patients, for patients without concomitant allergies, or for MCNS patients in
general, should be elucidated in future studies.

Data availability
No restrictions exist regarding the availability of data. Readers can obtain materials and information through
contacting corresponding author.

Received: 10 October 2019; Accepted: 16 January 2020;

Published: xx xx xxxx

References
1. Komatsuda, A. et al. GATA-3 is upregulated in peripheral blood mononuclear cells from patients with minimal change nephrotic
syndrome. Clin. Nephrol. 71, 608–616 (2009).
2. Stangou, M. et al. Impact of Tauh1 and Tauh2 cytokines in the progression of idiopathic nephrotic syndrome due to focal segmental
glomerulosclerosis and minimal change disease. J. nephropathology 6, 187–195, [Link] (2017).
3. Cho, B. S., Yoon, S. R., Jang, J. Y., Pyun, K. H. & Lee, C. E. Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal change
nephrotic syndrome. Pediatr. Nephrol. 13, 199–204 (1999).

Scientific Reports | (2020) 10:1490 | [Link] 8

[Link]/scientificreports/ [Link]/scientificreports

4. Yap, H. K. et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA
expression in relapse. J. Am. Soc. Nephrol. 10, 529–537 (1999).
5. van den Berg, J. G. & Weening, J. J. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin. Sci. 107,
125–136, [Link] (2004).
6. Sahali, D. et al. A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted
cDNA library screening. J. Am. Soc. Nephrol. 13, 1238–1247 (2002).
7. Liu, L. L. et al. Th17/Treg imbalance in adult patients with minimal change nephrotic syndrome. Clin. Immunol. 139, 314–320,
[Link] (2011).
8. Salcido-Ochoa, F. et al. Analysis of T Cell Subsets in Adult Primary/Idiopathic Minimal Change Disease: A Pilot Study. Int. J.
Nephrol. 2017, 3095425, [Link] (2017).
9. Araya, C. et al. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr. Nephrol. 24, 1691–1698, https://
[Link]/10.1007/s00467-009-1214-x (2009).
10. Lee, H. J. et al. GATA-3 induces T helper cell type 2 (Th2) cytokine expression and chromatin remodeling in committed Th1 cells. J.
Exp. Med. 192, 105–115 (2000).
11. Zhu, J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4)
and IL-13 production. Cytokine 75, 14–24, [Link] (2015).
12. Shi, Y. H. et al. Coexistence of Th1/Th2 and Th17/Treg imbalances in patients with allergic asthma. Chin. Med. J. 124, 1951–1956
(2011).
13. Endo, Y., Hirahara, K., Yagi, R., Tumes, D. J. & Nakayama, T. Pathogenic memory type Th2 cells in allergic inflammation. Trends
Immunol. 35, 69–78, [Link] (2014).
14. Roesner, L. M. et al. Der p1 and Der p2-Specific T Cells Display a Th2, Th17, and Th2/Th17 Phenotype in Atopic Dermatitis. J. Invest.
Dermatol. 135, 2324–2327, [Link] (2015).
15. Gu, Z. W., Wang, Y. X. & Cao, Z. W. Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2
and Th17 responses and upregulating the Treg response. Oncotarget 8, 22361–22369, [Link]
(2017).
16. Packard, K. A. & Khan, M. M. Effects of histamine on Th1/Th2 cytokine balance. Int. Immunopharmacol. 3, 909–920, [Link]
org/10.1016/s1567-5769(02)00235-7 (2003).
17. Fujimoto, S. et al. Histamine differentially regulates the production of Th1 and Th2 chemokines by keratinocytes through histamine
H1 receptor. Cytokine 54, 191–199, [Link] (2011).
18. Mazzoni, A., Young, H. A., Spitzer, J. H., Visintin, A. & Segal, D. M. Histamine regulates cytokine production in maturing dendritic
cells, resulting in altered T cell polarization. J. Clin. Invest. 108, 1865–1873, [Link] (2001).
19. Mommert, S., Gschwandtner, M., Koether, B., Gutzmer, R. & Werfel, T. Human memory Th17 cells express a functional histamine
H4 receptor. Am. J. Pathol. 180, 177–185, [Link] (2012).
20. Xue, L. et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk.
J. Allergy Clin. Immunol. 135(1358–1366), e1351–1311, [Link] (2015).
21. Lee, W., Su Kim, H. & Lee, G. R. Leukotrienes induce the migration of Th17 cells. Immunol. Cell Biol. 93, 472–479, [Link]
org/10.1038/icb.2014.104 (2015).
22. Xiao, J., Wu, W. X., Ye, Y. Y., Lin, W. J. & Wang, L. A Network Meta-analysis of Randomized Controlled Trials Focusing on Different
Allergic Rhinitis Medications. Am. J. Ther. 23, e1568–e1578, [Link] (2016).
23. Wei, C. The efficacy and safety of H1-antihistamine versus Montelukast for allergic rhinitis: A systematic review and meta-analysis.
Biomed. Pharmacother. 83, 989–997, [Link] (2016).
24. Zhang, H. P., Jia, C. E., Lv, Y., Gibson, P. G. & Wang, G. Montelukast for prevention and treatment of asthma exacerbations in adults:
Systematic review and meta-analysis. Allergy Asthma Proc. 35, 278–287, [Link] (2014).
25. Sharma, M., Bennett, C., Carter, B. & Cohen, S. N. H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane
Systematic Review. J. Am. Acad. Dermatol. 73, 710–716, e714, [Link] (2015).
26. de Silva, N. L., Damayanthi, H., Rajapakse, A. C., Rodrigo, C. & Rajapakse, S. Leukotriene receptor antagonists for chronic urticaria:
a systematic review. Allergy Asthma Clin. Immunol. 10, 24, [Link] (2014).
27. Roekevisch, E., Spuls, P. I., Kuester, D., Limpens, J. & Schmitt, J. Efficacy and safety of systemic treatments for moderate-to-severe
atopic dermatitis: a systematic review. J. Allergy Clin. Immunol. 133, 429–438, [Link] (2014).
28. Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score
matched samples. Stat. Med. 28, 3083–3107, [Link] (2009).
29. Zedan, M. M. et al. Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial. J.
nephrology 29, 585–592, [Link] (2016).
30. Abdel-Hafez, M., Shimada, M., Lee, P. Y., Johnson, R. J. & Garin, E. H. Idiopathic nephrotic syndrome and atopy: is there a common
link? Am. J. Kidney Dis. 54, 945–953, [Link] (2009).
31. Schulte-Wissermann, H., Gortz, W. & Straub, E. IgE in patients with glomerulonephritis and minimal-change nephrotic syndrome.
Eur. J. Pediatr. 131, 105–111, [Link] (1979).
32. Fuke, Y. et al. Implication of elevated serum IgE levels in minimal change nephrotic syndrome. Nephron 91, 769–770, [Link]
org/10.1159/000065049 (2002).
33. Miyazaki, K. et al. GSTT1 gene abnormality in minimal change nephrotic syndrome with elevated serum immunoglobulin E. Clin.
Nephrol. 77, 261–266, [Link] (2012).
34. Bertelli, R., Bonanni, A., Caridi, G., Canepa, A. & Ghiggeri, G. M. Molecular and Cellular Mechanisms for Proteinuria in Minimal
Change Disease. Front. Med. 5, 170, [Link] (2018).
35. Pirotzky, E. et al. Basophil sensitisation in idiopathic nephrotic syndrome. Lancet 1, 358–361 (1982).

Acknowledgements
This study was funded by the Okinaka Memorial Institute for Medical Research.

Author contributions
Y.O., K.S. and Y.U. designed the study; Y.O. collected and analyzed the data, prepared the figures and tables, and
drafted the manuscript; Y.O. and K.S. revised the manuscript; Y.O., K.S., M.Y., N.H., A.S., H.M., M.K., R.H., E.H.,
T.S., J.H., N.S., K.T. and Y.U. acquired data by treating the patients; T.F. supervised the renal histology analysis;
Y.U. supervised the overall study. All authors approved the final version of the manuscript.

Competing interests
The authors declare no competing interests.

Scientific Reports | (2020) 10:1490 | [Link] 9

[Link]/scientificreports/ [Link]/scientificreports

Additional information
Supplementary information is available for this paper at [Link]
Correspondence and requests for materials should be addressed to Y.O.
Reprints and permissions information is available at [Link]/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit [Link]

© The Author(s) 2020

Scientific Reports | (2020) 10:1490 | [Link] 10